167 related articles for article (PubMed ID: 37739958)
1. In vivo self-assembly and delivery of VEGFR2 siRNA-encapsulated small extracellular vesicles for lung metastatic osteosarcoma therapy.
Yu L; Fan G; Wang Q; Zhu Y; Zhu H; Chang J; Wang Z; Zhan S; Hua X; She D; Huang J; Wang Y; Zhao J; Zhang CY; Chen X; Zhou G
Cell Death Dis; 2023 Sep; 14(9):626. PubMed ID: 37739958
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis.
Liu JY; Zhu BR; Wang YD; Sun X
Int J Clin Oncol; 2020 Jun; 25(6):1195-1205. PubMed ID: 32215805
[TBL] [Abstract][Full Text] [Related]
3. Nanoscale polysaccharide derivative as an AEG-1 siRNA carrier for effective osteosarcoma therapy.
Wang F; Pang JD; Huang LL; Wang R; Li D; Sun K; Wang LT; Zhang LM
Int J Nanomedicine; 2018; 13():857-875. PubMed ID: 29467575
[TBL] [Abstract][Full Text] [Related]
4. Cancer combination therapies by silencing of CTLA-4, PD-L1, and TIM3 in osteosarcoma.
Sorkhabi AD; Sarkesh A; Fotouhi A; Saeedi H; Aghebati-Maleki L
IUBMB Life; 2022 Sep; 74(9):908-917. PubMed ID: 35638098
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effects of VEGF-siRNA mediated by adenovirus on osteosarcoma-bearing nude mice.
Gao YS; Mei J; Tong TL; Hu M; Xue HM; Cai XS
Cancer Biother Radiopharm; 2009 Apr; 24(2):243-7. PubMed ID: 19409047
[TBL] [Abstract][Full Text] [Related]
6. Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3.
Zheng B; Ren T; Huang Y; Guo W
Biochem Biophys Res Commun; 2018 Jan; 495(2):1695-1701. PubMed ID: 29225166
[TBL] [Abstract][Full Text] [Related]
7. Hydrophobicity of Lipid-Conjugated siRNAs Predicts Productive Loading to Small Extracellular Vesicles.
Biscans A; Haraszti RA; Echeverria D; Miller R; Didiot MC; Nikan M; Roux L; Aronin N; Khvorova A
Mol Ther; 2018 Jun; 26(6):1520-1528. PubMed ID: 29699940
[TBL] [Abstract][Full Text] [Related]
8. In vivo self-assembled small RNAs as a new generation of RNAi therapeutics.
Fu Z; Zhang X; Zhou X; Ur-Rehman U; Yu M; Liang H; Guo H; Guo X; Kong Y; Su Y; Ye Y; Hu X; Cheng W; Wu J; Wang Y; Gu Y; Lu SF; Wu D; Zen K; Li J; Yan C; Zhang CY; Chen X
Cell Res; 2021 Jun; 31(6):631-648. PubMed ID: 33782530
[TBL] [Abstract][Full Text] [Related]
9. siRNA targeting TCTP suppresses osteosarcoma cell growth and induces apoptosis in vitro and in vivo.
Shen JH; Qu CB; Chu HK; Cui MY; Wang YL; Sun YX; Song YD; Li G; Shi FJ
Biotechnol Appl Biochem; 2016; 63(1):5-14. PubMed ID: 25522670
[TBL] [Abstract][Full Text] [Related]
10. Self-assembled nanoparticles based on the c(RGDfk) peptide for the delivery of siRNA targeting the VEGFR2 gene for tumor therapy.
Liu L; Liu X; Xu Q; Wu P; Zuo X; Zhang J; Deng H; Wu Z; Ji A
Int J Nanomedicine; 2014; 9():3509-26. PubMed ID: 25114522
[TBL] [Abstract][Full Text] [Related]
11. Is it Possible to Treat Osteosarcoma Using Oligonucleotides Confined into Controlled Release Drug Delivery Systems?
Topuk S; Akyuva Y; Karaaslan N; Mutlu CA; Yilmaz I; Isyar M; Sirin DY; Akkaya S; Özbek H; Mahirogullari M
Curr Pharm Biotechnol; 2017; 18(6):516-522. PubMed ID: 28641566
[TBL] [Abstract][Full Text] [Related]
12. Functional genome screen for therapeutic targets of osteosarcoma.
Yamaguchi U; Honda K; Satow R; Kobayashi E; Nakayama R; Ichikawa H; Shoji A; Shitashige M; Masuda M; Kawai A; Chuman H; Iwamoto Y; Hirohashi S; Yamada T
Cancer Sci; 2009 Dec; 100(12):2268-74. PubMed ID: 19725836
[TBL] [Abstract][Full Text] [Related]
13. VEGF165 is necessary to the metastatic potential of Fas(-) osteosarcoma cells but will not rescue the Fas(+) cells.
Jia SF; Guan H; Duan X; Kleinerman ES
J Exp Ther Oncol; 2008; 7(2):89-97. PubMed ID: 18771083
[TBL] [Abstract][Full Text] [Related]
14. Extracellular vesicles secreted by highly metastatic clonal variants of osteosarcoma preferentially localize to the lungs and induce metastatic behaviour in poorly metastatic clones.
Macklin R; Wang H; Loo D; Martin S; Cumming A; Cai N; Lane R; Ponce NS; Topkas E; Inder K; Saunders NA; Endo-Munoz L
Oncotarget; 2016 Jul; 7(28):43570-43587. PubMed ID: 27259278
[TBL] [Abstract][Full Text] [Related]
15. Engineered small extracellular vesicle-mediated NOX4 siRNA delivery for targeted therapy of cardiac hypertrophy.
Kang JY; Mun D; Chun Y; Park DS; Kim H; Yun N; Joung B
J Extracell Vesicles; 2023 Oct; 12(10):e12371. PubMed ID: 37795828
[TBL] [Abstract][Full Text] [Related]
16. Delivery of mGluR5 siRNAs by Iron Oxide Nanocages by Alternating Magnetic Fields for Blocking Proliferation of Metastatic Osteosarcoma Cells.
Kang MA; Rao PP; Matsui H; Mahajan SS
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887290
[TBL] [Abstract][Full Text] [Related]
17. Extracellular Vesicle RNA Sequencing Reveals Dramatic Transcriptomic Alterations Between Metastatic and Primary Osteosarcoma in a Liquid Biopsy Approach.
Bao Q; Gong L; Wang J; Wen J; Shen Y; Zhang W
Ann Surg Oncol; 2018 Sep; 25(9):2642-2651. PubMed ID: 29981024
[TBL] [Abstract][Full Text] [Related]
18. KDM6B-mediated histone demethylation of LDHA promotes lung metastasis of osteosarcoma.
Jiang Y; Li F; Gao B; Ma M; Chen M; Wu Y; Zhang W; Sun Y; Liu S; Shen H
Theranostics; 2021; 11(8):3868-3881. PubMed ID: 33664867
[No Abstract] [Full Text] [Related]
19. Effects of combined c-myc and Bmi-1 siRNAs on the growth and chemosensitivity of MG-63 osteosarcoma cells.
Xie X; Ye Z; Yang D; Tao H
Mol Med Rep; 2013 Jul; 8(1):168-72. PubMed ID: 23685757
[TBL] [Abstract][Full Text] [Related]
20. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo.
Takeshita F; Minakuchi Y; Nagahara S; Honma K; Sasaki H; Hirai K; Teratani T; Namatame N; Yamamoto Y; Hanai K; Kato T; Sano A; Ochiya T
Proc Natl Acad Sci U S A; 2005 Aug; 102(34):12177-82. PubMed ID: 16091473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
